Nonalcoholic Fatty Liver Disease (NAFLD) Patient Pool Analysis Market to Reach USD 2.94 Billion by 2034

Pune, India - December 2025 - The global Nonalcoholic Fatty Liver Disease (NAFLD) Patient Pool Analysis Market, valued at USD 1.67 billion in 2024, is projected to reach USD 2.94 billion by 2034, growing at a 5.8% CAGR (2025-2034), according to Exactitude Consultancy. The rapid rise in obesity, type 2 diabetes, metabolic syndrome, and expanded liver health screening are increasing NAFLD patient identification worldwide.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71981

Market Summary
The NAFLD Patient Pool Analysis Market is expanding rapidly as NAFLD becomes one of the most prevalent liver disorders globally, affecting nearly 25-30% of the adult population. NAFLD ranges from simple steatosis to more severe forms such as nonalcoholic steatohepatitis (NASH), which can progress to fibrosis, cirrhosis, liver failure, and hepatocellular carcinoma (HCC). With obesity, diabetes, and sedentary lifestyles rising globally, NAFLD prevalence is increasing across all major regions.

Improved diagnostic adoption-including liver ultrasound, MRI-PDFF, transient elastography (FibroScan), blood-based fibrosis biomarkers, and AI-supported imaging-is helping clinicians more accurately stage disease severity. Growing awareness of metabolic liver disease is prompting earlier screening, particularly among high-risk groups such as diabetics and obese individuals. North America currently leads due to high disease prevalence and advanced diagnostics, while Asia-Pacific is the fastest-growing region, driven by lifestyle shifts and significant increases in metabolic diseases.

Key Takeaways
• 2024 Market Size: USD 1.67 Billion
• 2034 Forecast: USD 2.94 Billion
• CAGR: 5.8% (2025-2034)
• Nearly 30% of adults globally affected by NAFLD
• Expanded screening in metabolic clinics increasing patient pool accuracy
• Asia-Pacific shows fastest growth due to rising obesity & diabetes rates

Market Drivers
• Global rise in obesity, type 2 diabetes, and metabolic syndrome
• Increased adoption of imaging and non-invasive fibrosis assessment
• Growing clinical awareness of NAFLD and NASH progression risks
• Improved access to liver health diagnostics in emerging markets
• Strengthening epidemiological databases and real-world evidence sources

Segmentation Snapshot
By Disease Stage
• Simple Steatosis (NAFL)
• Nonalcoholic Steatohepatitis (NASH)
• Fibrosis (F1-F4)
• Cirrhosis
• Hepatocellular Carcinoma (HCC Risk Group)

By Diagnostic Method
• Ultrasound
• MRI-PDFF
• FibroScan / Elastography
• Blood Biomarkers (ALT/AST, FIB-4, ELF Test)
• Liver Biopsy (Gold Standard)
• AI-Based Liver Imaging

By Risk Group
• Obese Patients
• Diabetic Patients
• Metabolic Syndrome Population
• Elderly Individuals
• High-Risk Ethnic Groups

By End User
• Hospitals
• Liver Specialty Clinics
• Diagnostic & Imaging Centers
• Metabolic Health Centers
• Research Institutions

By Region
• North America (Largest Patient Pool Coverage)
• Europe
• Asia-Pacific (Fastest Growing)
• Latin America
• Middle East & Africa

Explore Full Report here: https://exactitudeconsultancy.com/reports/71981/nonalcoholic-fatty-liver-disease-nafld-patient-pool-analysis-market

Recent Developments
• Increased adoption of FibroScan for non-invasive fibrosis assessment.
• Growth in AI-enabled liver imaging tools for NAFLD/NASH risk stratification.
• Strengthening metabolic liver disease registries worldwide.
• Clinical advancement of NASH therapeutics improving the need for accurate staging.

Expert Quote - Irfan Tamboli, Business Development Executive
"NAFLD has become one of the most common liver disorders worldwide, driven by lifestyle and metabolic risk factors. As diagnostics improve and screening expands, the global NAFLD patient pool is becoming more accurately defined-critical for both prevention and therapeutic development."

Conclusion
The NAFLD Patient Pool Analysis Market will continue expanding through 2034 as global metabolic disease rates increase, liver screening becomes more widespread, and diagnostic innovation accelerates. Companies focusing on non-invasive fibrosis tools, AI imaging technologies, and epidemiological modeling will play a pivotal role in shaping future NAFLD insights.

This report is also available in the following languages : Japanese (非アルコール性脂肪性肝疾患(NAFLD)患者プール分析、市場), Korean (비알코올성 지방간 질환(NAFLD) 환자 풀 분석, 시장), Chinese (非酒精性脂肪肝 (NAFLD) 患者群体分析,市场), French (Analyse du marché des patients atteints de stéatose hépatique non alcoolique (NAFLD)), German (Analyse des Patientenpools für nichtalkoholische Fettlebererkrankung (NAFLD), Markt), and Italian (Analisi del pool di pazienti affetti da steatosi epatica non alcolica (NAFLD), mercato), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/71981

Related Reports
Liver Health Supplements Market
https://exactitudeconsultancy.com/reports/50074/liver-health-supplements-market

Liver Disease Diagnostics Market
https://exactitudeconsultancy.com/reports/60344/global-liver-disease-diagnostics-market

Non-Alcoholic Fatty Liver Disease (NAFLD) Drug Market
https://exactitudeconsultancy.com/reports/70426/non-alcoholic-fatty-liver-disease-nafld-drug-market

Non Alcoholic Fatty Liver Disease Market
https://exactitudeconsultancy.com/reports/71124/non-alcoholic-fatty-liver-disease-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.